Monday June 25, 2012 0 commentsWESTMINSTER - Surefire Medical Inc. announced it has received 510(k) FDA clearance to market the Surefire High-Flow Microcatheter, the next generation of the company's infusion technology.
The system is designed to deliver therapy with higher infusion efficiency than conventional microcatheters, the company said.
Pre-clinical study results presented at the World Congress of Interventional Oncology in June 2011 found the Surefire Infusion System achieved an average infusion efficiency of 99.1 percent compared to 72.8 percent with a standard infusion catheter.
"Working with key interventional radiologists, our research and development team has created a highly trackable, sleek microcatheter designed to accommodate smaller vessels and selective procedures," said Jim Chomas, Surefire CEO.
"The addition of the Surefire High-Flow Microcatheter will enable physicians to treat more patients with addressable disease."
Since its launch in August 2011, the initial Surefire Infusion System has been used in 68 high-volume, top-tier hospitals, primarily in interventional procedures to treat primary and secondary liver cancer.
For more information, visit www.surefiremedical.com.